BRIUMVI
Total Payments
$14.4M
Transactions
21,436
Doctors
4,155
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.3M | 12,851 | 3,111 |
| 2023 | $4.0M | 8,585 | 2,508 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.0M | 1,309 | 48.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.8M | 1,453 | 33.6% |
| Consulting Fee | $1.1M | 612 | 7.5% |
| Travel and Lodging | $693,561 | 1,310 | 4.8% |
| Food and Beverage | $607,673 | 16,612 | 4.2% |
| Space rental or facility fees (teaching hospital only) | $97,775 | 27 | 0.7% |
| Grant | $33,600 | 1 | 0.2% |
| Charitable Contribution | $30,000 | 2 | 0.2% |
| Education | $2,645 | 110 | 0.0% |
Payments by Type
General
$7.4M
20,127 transactions
Research
$7.0M
1,309 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| (ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab | TG Therapeutics, Inc. | $3.5M | 0 |
| TG1101-RMS303 An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | TG Therapeutics, Inc. | $2.1M | 0 |
| (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study | TG Therapeutics, Inc. | $571,954 | 0 |
| (ENHANCE) Evaluating Efficacy of a Modified Regimen of Ublituximab | TG Therapeutics, Inc. | $329,536 | 0 |
| Retrospective Evaluation of Infusion Tolerability: BRIUMVI Real-World Observational Survey (ENAMOR) | TG Therapeutics, Inc. | $159,500 | 1 |
| Effects of Ublituximab on Unperturbed and Perturbed Ambulatory Functions in People with Relapsing Multiple Sclerosis | TG Therapeutics, Inc. | $65,817 | 0 |
| An Open-Label, Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201 Treated with Ublituximab for Relapsing Forms of Multiple Sclerosis | TG Therapeutics, Inc. | $61,475 | 0 |
| Retrospective analysis of natalizumab switches to ublituximab in patients with relapsing multiple sclerosis (MS) | TG Therapeutics, Inc. | $52,260 | 0 |
| Incomplete B-cell Suppression in Patients on ocrelizumab: Does Switching to ublituximab Make a Difference? | TG Therapeutics, Inc. | $51,778 | 2 |
| ENAMOR | TG Therapeutics, Inc. | $41,000 | 0 |
| An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | TG THERAPEUTICS, INC. | $14,700 | 1 |
| A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis. | TG Therapeutics, Inc. | $14,017 | 0 |
| Retrospective Analysis of natalizumab Switches to ublituximab Relapsing Multiple Sclerosis (MS) | TG Therapeutics, Inc. | $13,065 | 1 |
| RMS302 | TG Therapeutics, Inc. | $12,070 | 7 |
| RMS301 | TG Therapeutics, Inc. | $5,023 | 6 |
| An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis | TG Therapeutics, Inc. | $3,600 | 1 |
Top Doctors Receiving Payments for BRIUMVI — Page 7
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Specialist | Englewood, CO | $8,445 | 17 |
| , D.O | Student in an Organized Health Care Education/Training Program | Reading, PA | $8,419 | 13 |
| , MD | Neurology | New York, NY | $8,409 | 18 |
| , M.D | Neurology | Los Angeles, CA | $8,352 | 11 |
| , MD | Neurology | New York, NY | $8,247 | 8 |
| , MBCHB MRCP(UK) | Neurology | Kansas City, KS | $8,067 | 14 |
| , N.P | Nurse Practitioner | Lake Barrington, IL | $7,675 | 33 |
| , M.D | Neurology | Brewer, ME | $7,608 | 11 |
| , MD | Neurology | New York, NY | $7,589 | 22 |
| , M.D | Neurology | Boston, MA | $7,511 | 8 |
| , MD | Neurology | Independence, OH | $7,470 | 9 |
| , MD | Neurology | Palo Alto, CA | $7,464 | 7 |
| , MD | Neurology | Boston, MA | $7,303 | 4 |
| , M.D | Neurology | Overland Park, KS | $7,249 | 10 |
| , M.D | Neurology | Santa Monica, CA | $7,161 | 6 |
| , MD | Neurology | Sarasota, FL | $6,827 | 7 |
| , MD | Neurology | Saint Louis, MO | $6,702 | 7 |
| , M.D | Hematology & Oncology | Boston, MA | $6,625 | 1 |
| , MD | Student in an Organized Health Care Education/Training Program | Hartford, CT | $6,566 | 3 |
| , M.D | Neurology | Grand Rapids, MI | $6,498 | 10 |
| , FNP | Family | Kansas City, MO | $6,462 | 26 |
| , MD | Neurology | Columbus, OH | $6,447 | 7 |
| , M.D | Neurology | New York, NY | $6,345 | 10 |
| , M.D | Neurology | Dallas, TX | $6,201 | 4 |
| , MS, AGPCNP-BC | Registered Nurse | New York, NY | $6,176 | 20 |
Ad
Manufacturing Companies
- TG Therapeutics, Inc. $14.0M
- TG THERAPEUTICS, INC. $341,969
Product Information
- Type Drug
- Total Payments $14.4M
- Total Doctors 4,155
- Transactions 21,436
About BRIUMVI
BRIUMVI is a drug associated with $14.4M in payments to 4,155 healthcare providers, recorded across 21,436 transactions in the CMS Open Payments database. The primary manufacturer is TG Therapeutics, Inc..
Payment data is available from 2023 to 2024. In 2024, $10.3M was paid across 12,851 transactions to 3,111 doctors.
The most common payment nature for BRIUMVI is "Unspecified" ($7.0M, 48.7% of total).
BRIUMVI is associated with 16 research studies, including "(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab" ($3.5M).